Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 351-360 of 10529

Edit search filters
  1. Study Evaluating Intepirdine (RVT-101) in Subjects With Dementia With Lewy Bodies: The HEADWAY-DLB Study

    Jacksonville, FL, Rochester, MN

  2. A Study of the Long-Term Safety of Tafamidis for Patients with Transthyretin Cardiomyopathy

    Rochester, MN

  3. Abemaciclib Versus Placebo in Patients With Advanced Dedifferentiated Liposarcoma

    Jacksonville, FL

  4. A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants

    Rochester, MN

  5. Mediterranean Diet Post-liver Transplantation

    Rochester, MN

  6. FORMA Study

    Rochester, MN

  7. A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome

    Rochester, MN

  8. A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

    Scottsdale/Phoenix, AZ

  9. Enhancing the Natriuretic Peptide System in HFpEF

    Rochester, MN

  10. Cara CDRM (Conduction Disturbance Risk Monitor) 2.0

    Rochester, MN

.

Mayo Clinic Footer